1. What Is the KRAS Inhibitor Market?
The KRAS Inhibitor Market covers the covalent and non-covalent small molecule inhibitors targeting the mutated KRAS oncogene that is the most frequently mutated oncogene in human cancer. Over 30 percent of all cancers harbour the KRAS mutation. The KRAS G12C covalent inhibitors sotorasib and adagrasib lock the KRAS G12C in the inactive GDP-bound state through the cysteine reactive warhead. The pan-KRAS and KRAS G12D non-covalent inhibitors that the second generation is developing extend KRAS targeting beyond the 13 percent KRAS G12C subtype. The larger G12D at 40 percent and G12V at 23 percent mutation populations are the next targets. The KRAS G12C inhibitor FDA approval represented the pivotal breakthrough for the oncogene that structural biologists declared undruggable for over 40 years. The smooth featureless surface without the binding groove that conventional drug design identified in the KRAS protein blocked the drug development. The GDP-bound state allosteric pocket that the covalent cysteine inhibitor occupies was discovered after decades of effort. The KRAS inhibitor market is evolving with the SOS1 inhibitor and the KRAS-SOS1 PPI disruptor combinations. The on-target KRAS G12C resistance from the SOS1-mediated KRAS reloading with GTP that the GDP-locked covalent inhibitor cannot prevent requires the co-inhibition of the RAS-GEF that reactivates KRAS.
2. KRAS Inhibitor Market Size & Forecast
3. Emerging Technologies
- KRAS G12C covalent inhibitor mechanism locks the KRAS G12C in the GDP-bound inactive state through the irreversible covalent bond formed with the cysteine 12 residue that the G12C mutation introduces. The bond prevents the GDP-to-GTP exchange that the GEF catalyses to convert KRAS to the active GTP-bound form. The active form drives the MAPK and PI3K signalling that the cancer cell requires for the proliferation and the survival that the oncogenic KRAS constitutively activates.
- Adagrasib CodeBreaK 200 head-to-head versus docetaxel in the second-line NSCLC KRAS G12C demonstrated 25 versus 22-week PFS with the confirmed ORR advantage and the CNS activity against the brain metastases. The 12 percent CNS objective response in the patients with untreated brain metastases demonstrates the CNS penetration that adagrasib achieves. The NSCLC patient commonly develops the brain metastases that the KRAS inhibitor must reach.
- KRAS G12D inhibitor development uses the non-covalent binding strategy that must achieve the GTP-competitive or the allosteric binding to the G12D mutant KRAS. The G12D mutant lacks the cysteine that the G12C covalent strategy exploits. The MRTX1133 from Mirati and the RMC-9805 from Revolution Medicines are progressing through Phase I dose escalation.
- KRAS pan-RAS inhibitor RMC-6236 from Revolution Medicines uses the cyclophilin A ternary complex mechanism that traps the active KRAS in the state that the cyclophilin binding stabilises. The trapped state blocks the KRAS-effector interaction. The GTP-state KRAS inhibitor reaches the non-G12C KRAS mutations that the GDP-state G12C covalent inhibitor cannot achieve.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Lung Cancer Drug Market.
4. Key Market Opportunity
Substantial growth potential in the KRAS Inhibitor market is KRAS G12D inhibitor development, where clinical validation of G12D targeting would open the most prevalent KRAS mutation in pancreatic and other cancers. Companies first demonstrating strong G12D clinical activity capture the defining KRAS oncology breakthrough. A parallel growth driver is driven by first-line KRAS G12C combination therapy developing beyond second-line monotherapy. As G12D inhibitors advance and first-line KRAS combination data accumulates, the addressable opportunity is expanding from approved second-line G12C monotherapy toward first-line combination and G12D-targeted therapy across NSCLC, CRC, and PDAC.
5. Top Companies in the KRAS Inhibitor Market
The following organisations hold leading positions in the KRAS Inhibitor Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Amgen
- Bristol-Myers Squibb
- Revolution Medicines
- Eli Lilly
- Roche
- Boehringer Ingelheim
- Jacobio Pharmaceuticals
- AstraZeneca
- Frontier Medicines
- BeiGene
6. Market Segmentation
The KRAS Inhibitor Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Mutation | KRAS G12CKRAS G12DKRAS G12VPan-KRAS |
| By Drug | SotorasibAdagrasibPipeline |
| By Tumour Type | NSCLCCRCPDAC |
| By Line | Second-LineFirst-Line Combination |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the KRAS Inhibitor Market trajectory over the forecast period:
KRAS G12C Covalent Cysteine 12 Inhibitor Sotorasib and Adagrasib Breaking the 40-Year Undruggable Oncogene Barrier Through the GDP-Bound Allosteric Pocket Have Achieved FDA Approval for the 13 Percent of NSCLC and CRC Patients With the G12C Mutation.Amgen's sotorasib demonstrated 37.1% response rate and 5.6-month median PFS in previously treated KRAS G12C NSCLC in CodeBreaK 100, and Mirati's adagrasib demonstrated 43% response rate in KRYSTAL-1, establishing direct KRAS inhibition as a viable clinical approach that challenges the pre-clinical consensus that KRAS's smooth protein surface could not accommodate small-molecule binding. Both agents exploit the GDP-bound inactive state of the G12C mutant's novel cysteine that allows covalent binding exclusively to the mutant protein, leaving wild-type KRAS unaffected and creating a true precision oncology window. The KRAS G12C population in NSCLC represents approximately 13% of adenocarcinoma patients, defining a patient segment of roughly 25,000 US cases annually where precision therapy is now the second-line standard.
Adagrasib CodeBreaK 200 CNS Activity 12 Percent Objective Response in Untreated NSCLC Brain Metastases Demonstrating Blood-Brain Barrier Penetration Has Differentiated the Second-Generation KRAS G12C Inhibitor for the Brain Metastasis Setting That First-Line KRAS Inhibitors Commonly Face.Adagrasib combined with cetuximab demonstrated 46% response rate in KRAS G12C colorectal cancer versus historical 17-19% for adagrasib monotherapy in KRYSTAL-10, and the EVEREST and SIERRA trials are evaluating sotorasib plus panitumumab in the same indication. The EGFR-combination rationale stems from EGFR-driven adaptive resistance where KRAS G12C inhibitor treatment releases negative feedback on upstream RAS-pathway signalling, allowing wild-type EGFR to substitute for mutant KRAS in driving tumour cell proliferation. KRAS G12C colorectal cancer has historically been associated with poor prognosis and poor response to EGFR antibodies, making the combination's reversal of both limitations a clinically important breakthrough.
KRAS G12D Non-Covalent Inhibitors MRTX1133 and RMC-9805 in Phase I Extending KRAS Targeting Beyond the G12C Cysteine Exploitable by Covalent Strategy to the 40 Percent G12D Mutation Are Expanding the KRAS Inhibitor Addressable Cancer Population.Major advance Medicines's RMC-6236 KRASG12X mutant-selective pan-RAS inhibitor demonstrated tumour shrinkage in KRAS G12D, G12V, G12R, and G12C pancreatic cancer patients in Phase 1 data, addressing the 75% of KRAS mutations in pancreatic cancer that the G12C-selective covalent approach cannot reach. RMC-9805 selective KRAS G12D inhibitor and Boehringer Ingelheim BI-2701 are advancing as the most concentrated programmes in the highest-prevalence KRAS mutation that drives pancreatic cancer, lung cancer, and colorectal cancer simultaneously. The clinical validation of G12D inhibition would unlock the largest KRAS-mutant population , exceeding the G12C niche that sotorasib and adagrasib occupy , and represents the commercially significant remaining milestone in the KRAS inhibitor field.
For related market intelligence, see the Oncology Drug Market.
8. Segmental Analysis
By mutation, the KRAS G12C segment dominated the KRAS Inhibitor Market in 2025, as Amgen's Lumakras and Bristol-Myers Squibb's Krazati secured approvals in non-small-cell lung and colorectal cancer, generating the first commercial revenue for direct KRAS inhibition after decades of the target being considered undruggable.
By tumour type, the gastrointestinal cancer segment is projected to register the highest growth rate through 2034, as Major advance Medicines and Boehringer Ingelheim advance G12D and pan-RAS inhibitors into pancreatic and colorectal cancer, where KRAS alterations dominate and represent the larger commercial opportunity.
9. Regional Analysis
Regional demand patterns across the KRAS Inhibitor Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the KRAS Inhibitor Market in 2025, accounting for approximately 44% of global revenue, due to US approval and commercial launch of sotorasib and adagrasib and the concentration of Amgen, Bristol-Myers Squibb, and Revolution Medicines KRAS development. Moreover, KRAS mutation testing and inhibitor prescribing are most advanced in US oncology. In addition, combination KRAS development is centred in North American clinical programmes. Regional dominance is attributed to this combination of first-mover commercial presence and pipeline concentration.
Highest CAGR Region
Europe is projected to register the highest CAGR in the KRAS Inhibitor Market through 2034, driven by expanding sotorasib and adagrasib access across European markets and KRAS G12D clinical trial participation growing as European oncology centres join pan-KRAS and G12D programmes. The region is also witnessing KRAS mutation testing infrastructure building. Moreover, CRC and NSCLC KRAS inhibitor adoption is growing. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The KRAS Inhibitor Market was valued at USD 1.20 Bn in 2025 and is projected to reach USD 14.59 Bn by 2034, growing at a CAGR of 32.0% over the 2026–2034 forecast period.
The KRAS Inhibitor Market is projected to grow at a CAGR of 32.0% from 2026 to 2034.
North America dominated the KRAS Inhibitor Market in 2025, accounting for approximately 44% of global revenue, due to US approval and commercial launch of sotorasib and adagrasib and the concentration of Amgen, Bristol-Myers Squibb, and Revolution Medicines KRAS development.
The leading companies in the KRAS Inhibitor Market include Amgen, Bristol-Myers Squibb, Revolution Medicines, Eli Lilly, Roche, Boehringer Ingelheim, Jacobio Pharmaceuticals, AstraZeneca, Frontier Medicines, BeiGene.
Kras g12c covalent cysteine 12 inhibitor sotorasib and adagrasib breaking the 40-year undruggable oncogene barrier through the gdp-bound allosteric pocket have achieved fda approval for the 13 percent of nsclc and crc patients with the g12c mutation.
By mutation, the KRAS G12C segment dominated the KRAS Inhibitor Market in 2025, as Amgen's Lumakras and Bristol-Myers Squibb's Krazati secured approvals in non-small-cell lung and colorectal cancer, generating the first commercial revenue for direct KRAS inhibition after decades of the target being considered undruggable.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.